Coherus Oncology, Inc. (FRA:8C5)

Market Cap	219.75M +34.4%
Revenue (ttm)	236.71M +152.1%
Net Income	132.08M
EPS	1.14
Shares Out	n/a
PE Ratio	1.66
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,818
Average Volume	881
Open	1.525
Previous Close	1.338
Day's Range	1.525 - 1.807
52-Week Range	0.608 - 1.807
Beta	n/a
RSI	72.82
Earnings Date	Mar 6, 2026

About Coherus Oncology

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 mono...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 158
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8C5

Financial Performance

Financial numbers in USD